type ii diabetes

TMPA is a nuclear receptor Nur77 and LKB1 interaction antagonist.

Bimagrumab (BYM338) is a human monoclonal antibody that binds to the activin type II receptor. Bimagrumab can be used to study diabetes and obesity.

Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes.

16α-Bromoepiandrosterone (BEA) is a water-soluble synthetic sterol related to DHEA and is used in studies of type II diabetes and non-diabetic tuberculosis infections.

LI-2242 is a potent inositol hexakisphosphate kinase (IP6K) inhibitor with IC50s of 31 nM, 42 nM, 8.7 nM, and 1944 nM for IP6K1, IP6K2, IP6K3, and IPMK, respectively.LI-2242 ameliorated hepatic steatosis by reducing the expression of genes that enhance lipid uptake, lipid stabilization, and adipogenesis, and enhanced mitochondrial oxygen consumption rate (OCR) and insulin signaling in adipocytes and hepatocytes in vitro. LI-2242 ameliorated diet-induced obesity, hyperglycemia and hepatic steatosis in mice.LI-2242 can be used to study type II diabetes, obesity, metabolic complications, venous thrombosis and psychiatric disorders.

Ebaresdax hydrochloride has analgesic activity and is used in the study of painful diabetic neuropathy caused by type I or type II diabetes.

Nampt activator-2 is a NAMPT activator (EC50: 0.023 μM). Nampt activator-2 has an affinity for CYP2C9, 2D6, and 2C19 with affinity values of 0.060 μM, 0.41 μM, and 0.59 μM, respectively.Nampt activator-2 can be used in the study of atherosclerosis, obesity, type II diabetes, insulin resistance, and type I diabetes.

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

Canagliflozin (JNJ 28431754AAA) is a selective SGLT2 inhibitor that inhibits CHO cells expressing mSGLT2, rSGLT2, and hSGLT2 (IC50=2/3.7/4.4 nM). Canagliflozin can be used for the treatment of type II diabetes mellitus (T2DM).

D-Tagatose (D-(-)-Tagatose), a rare natural hexoketose and isomer of D-galactose, occurs naturally in Sterculia setigera gum and is found in small quantities in various foods such as sterilized and powdered cow's milk, hot cocoa, and various cheeses, yogurts, and other dairy products. It can be synthesized from D-galactose by isomerization under alkaline conditions in the presence of calcium. D-Tagatose has numerous health benefits, including promotion of weight loss, no glycemic effect, anti-plaque, non-cariogenic, anti-halitosis, prebiotic, and anti-biofilm properties; it is beneficial for organ transplants, enhancement of flavor, improvement of pregnancy and fetal development, treatment of obesity, and reduction in symptoms associated with type 2 diabetes, hyperglycemia, anemia, and hemophilia. (PMID: 17492284).

Efpeglenatide is a long-acting agonist of the glucagon-like peptide-1 (GLP-1) receptor. Efpeglenatide improves insulin sensitivity, lowers blood glucose levels, and delays weight gain in diabetic and obese mouse models. Efpeglenatide has been applied in Type 2 diabetes research, providing an efficient experimental tool and preclinical evaluation value for developing metabolic disease intervention strategies, investigating weight loss mechanisms, and exploring insulin signaling regulation pathways.

'3'-Hydroxy Repaglinide, a primary CYP2C8 metabolite of Repaglinide, is derived from carbamoylmethyl benzoic acid and is used in the treatment of type II diabetes.

AM-1638 is an orally active GPR40/FFA1 agonist, useful for studying type II diabetes.

GLP-1R agonist 25 (compound 13) is a GLP1-R agonist with an EC50 of 0.167 nM and is utilized in research for Type II diabetes.

JNJ-41443532 Free Base is an oral CCR2 receptor antagonist used in the treatment of type 2 diabetes. The compound has completed a Phase I trial with healthy volunteers in Belgium and a Phase II trial involving type 2 diabetes patients in the United States.

Dyrk1A-IN-7 (Compound 29) is a selective DYRK1A kinase inhibitor with notable kinase selectivity, exhibiting an IC50 value of 28 nM for DYRK1A and a Kd of 17.5 nM for CLK2. This selective inhibitor is applicable in research related to cancer, type II diabetes, and neurological disorders.

GPR40 agonist 8 (Compound 2) is a GPR40 agonist with an EC50 value of 5 nM for hGPR40Ca2+. It is applicable in research related to type II diabetes and obesity.

Naperiglipron (LY3549492) (Example 2) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 1.14 nM for hGLP-1R. It markedly reduces blood glucose levels in GLP-1R gene knock-in mouse models. Additionally, Naperiglipron inhibits PDE10A1 enzyme activity (IC50: 7.43 μM) and exhibits weak hERG inhibitory activity. This compound is applicable in research on Type II diabetes mellitus (T2DM) and obesity.

DSA8 is a type II kinase inhibitor with IRE1 ribonuclease regulatory activity. It is applicable for research in cancer and metabolic diseases, such as diabetes.

D-α-Methyl DOPA is an inhibitor of DQ8 peptide binding to MHC class II molecules. By occupying a binding site in the DQ8 peptide groove, D-α-Methyl DOPA prevents the DQ8 peptide from associating with MHCII molecules. This action blocks presentation to CD4+ T cells, thereby slowing or hindering the onset or progression of type 1 diabetes or celiac disease.

TT01001 (Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate) is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.

BMS-986118 is a full agonist of GPR40, is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial a

Naveglitazar (LY 519818, LY 9818) is a peroxisome proliferator-activated receptor (PPAR) modulator, which has entered phase II clinical trials for the treatment of type 2 diabetes.

(E)-Guggulsterone is an isomer of guggulsterone. As an FXR antagonist, it reduces blood lipids, induces heme oxygenase-1 expression, blocks DENV NS2B/3B activity, and inhibits DENV replication.